Field Trip Health Ltd. to Commence Trading on the NASDAQ on July 29, 2021 Under the Symbol FTRP
July 27 2021 - 3:32PM
Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field
Trip" or the “Company”), a global leader in the development and
delivery of psychedelic therapies, announced today that it has
received final approval from The NASDAQ Stock Market LLC (“NASDAQ”)
to list its common shares on the NASDAQ Global Select Market. The
Company’s shares will begin trading at market open on Thursday,
July 29, 2021 with the ticker symbol FTRP.
Hannan Fleiman, Field Trip’s President, said
“Listing on the Nasdaq Global Select Market, NASDAQ’s top tier, is
a mark of achievement and stature for listed companies who must
meet the highest the highest financial and liquidity qualifications
for inclusion. We are proud of the rapid progress we have made in a
relatively short period of time and this accomplishment is a
testament to the efforts of our employees and partners. We look
forward to building value for our shareholders as we enter the next
stage of our growth.”
Dr. Ryan Yermus, Field Trip’s Chief Clinical
Officer, added, “Listing on the leading securities exchange for
biotech companies will enable more investors both in the U.S. and
globally to support Field Trip as we advance our ground-breaking
work in the psychedelics industry. We continue to make steady
progress with the development of FT-104, a novel psychedelic
molecule, with GMP production underway in preparation for Phase 1
studies, and other strategic initiatives which will further
strengthen our leadership position in the industry.”
The Company’s common stock will continue to
trade in Canada on the Toronto Stock Exchange (TSX) under its
current symbol FTRP; and concurrent with the listing of Field
Trip’s common shares on NASDAQ in the US, the shares will cease to
be quoted on the OTCQX. The Company has previously completed the
process to ensure its shares are eligible for electronic clearing
and settlement through the Depository Trust Company (DTC).
Concurrent with the listing, Ronan Levy and
Ellen Lubman will join the compensation committee and Mujeeb
Jafferi and Dr. Ryan Yermus will resign as directors of the
Company. Mr. Jafferi and Dr. Yermus will continue to serve as Field
Trip’s Chief Operating Officer and Chief Clinical Officer,
respectively.
About Field Trip Health Ltd.
Field Trip is a global leader in the development
and delivery of psychedelic therapies. With our Field Trip
Discovery division leading the development of the next generation
of psychedelic molecules and conducting advanced research on
plant-based psychedelics and our Field Trip Health division
building centers for psychedelic therapies opening across North
America and Europe along with the digital and technological tools
that will enable massive scale, we help people in need with a
simple, evidence-based way to heal and heighten engagement with the
world.
Learn more at https://www.meetfieldtrip.com,
https://www.fieldtriphealth.com and
https://www.fieldtriphealth.nl.
Follow us on Twitter and Instagram:
@fieldtriphealth
To receive company updates about Field Trip and
to be added to the email distribution list please sign up here.
For further information, contact Ronan Levy,
Executive Chairman and a Director at Field Trip, at 1 (833)
833-1967.
Cautionary Note Regarding Forward-Looking
Information.
This release includes forward-looking
information within the meaning of Canadian securities laws
regarding Field Trip and its business. Often but not always,
forward-looking information can be identified by the use of words
such as "expect", "intends", "anticipated", "believes" or
variations (including negative variations) of such words and
phrases, or state that certain actions, events or results "may",
"could", "would" or "will" be taken, occur or be achieved. Such
statements are based on the current expectations and views of
future events of the management of Field Trip, and are based on
assumptions and subject to risks and uncertainties. Although the
management of Field Trip believes that the assumptions underlying
these statements are reasonable, they may prove to be incorrect.
The forward-looking events and circumstances discussed in this
release may not occur and could differ materially as a result of
known and unknown risk factors and uncertainties affecting the
companies, including the timing and results of its research and
development programs, approval of phase 1 human trials, if any, the
risk that future clinical studies may not proceed as expected or
may produce unfavorable results, the opening of additional clinics,
the COVID-19 epidemic, the medical clinic industry, market
conditions, economic factors, management's ability to manage and to
operate the business and the equity markets generally. Although
Field Trip has attempted to identify important factors that could
cause actual actions, events or results to differ materially from
those described in forward-looking statements, there may be other
factors that cause actions, events or results to differ from those
anticipated, estimated or intended. Accordingly, readers should not
place undue reliance on any forward-looking statements or
information. No forward-looking statement can be guaranteed. Except
as required by applicable securities laws, forward-looking
statements speak only as of the date on which they are made and
Field Trip does not undertake any obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events, or otherwise.
Neither the Toronto Stock Exchange, nor its
Regulation Services Provider, nor the OTC Markets have approved the
contents of this release or accept responsibility for the adequacy
or accuracy of this release.
Media contacts:Rachel MoskowitzAutumn
Communications202-276-7881press@fieldtriphealth.com
Nick Opich / McKenna MillerKCSA Strategic
Communications212-896-1206 /
347-487-6197press@fieldtriphealth.com
Investor contacts:Elizabeth BarkerKCSA
Strategic Communications212-896-1203ebarker@kcsa.com
SOURCE Field Trip Health Ltd.
Field Trip Health (TSX:FTRP.WT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Field Trip Health (TSX:FTRP.WT)
Historical Stock Chart
From Sep 2023 to Sep 2024